| 应用 |
The free base form of an FGFR inhibitor |
| 产品介绍 |
Dovitinib (TKI-258, CHIR-258)是一种多靶点的RTK抑制剂，对III型(FLT3/c-Kit)作用最强，IC50为1 nM/2 nM，同时也作用于IV类(FGFR1/3)和V类(VEGFR1-4) RTKs，IC50为8-13 nM，但对InsR， EGFR， c-Met， EphA2， Tie2， IGF-1R和HER2作用较弱。 |
| 备注 |
Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-M |
| 生化机理 |
Dovitinib, Free Base, is the non-salt form of dovitinib, lactate salt (sc-396753). Dovitinib is a multitargeted growth factor receptor kinase inhibitor to VEGFR, FGFR3, PDGFR and c-KIT. |
| 别名 |
CHIR-258;多韦替尼; 4-氨基-5-氟-3-[5-(4-甲基哌嗪-1-基)-1H-苯并咪唑-2-基]喹啉-2(1H)-酮;CHIR-258;TKI258;TKI-258;TKI 258;CHIR258;CHIR 258;4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one |
